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                Abstract 
 
 
Introduction: Smoking-related COPD is a worldwide health problem. Airway 
remodelling is defined as structural changes occurring in chronic inflammatory diseases 
of the airways. Our knowledge about airway remodelling in COPD is very limited. My 
preliminary observational study of bronchial biopsies (BB) from COPD subjects 
revealed reticular basement membrane (Rbm) fragmentation and vascular changes. I 
hypothesised that these changes are specific for COPD and are related to the angiogenic 
activity of vascular endothelial growth factor (VEGF) and transforming growth factor-ß 
(TGF-ß). I also aimed to study the effects of inhaled corticosteroids (ICS) on these 
airway changes.   
 
Methods: A cross-sectional study compared BB from current smokers with COPD (S-
COPD), ex-smokers with COPD (ES-COPD), current smokers with normal lung 
function (S-N) and healthy nonsmoking (H-N) subjects. BB were stained with anti-
Collagen IV, anti-VEGF and anti-TGF- ß antibodies. Rbm fragmentation and vessels in 
the Rbm and lamina propria (LP) were measured. Anti-Factor VIII antibody was 
compared with anti-Collagen IV antibody in detecting vessels. 
  
Then a double-blind, randomized and placebo controlled study assessed the effects of 
ICS on airway remodeling, VEGF and TGF- ß in COPD.  
 
Results: Airway remodelling changes were also detectable in S-N. The Rbm was 
fragmented. The length of splits was significantly greater in both COPD groups and in 
S-N than controls (p<0.02). The Rbm was hypervascular and the LP hypovascular in 
current smokers compared with controls (p<0.05). Vessels stained for VEGF and TGF-ß 
were increased in the Rbm of both COPD groups and S-N (p<0.05). Factor VIII 
antibody confirmed my finding of hypovascularity of the LP in S-COPD. ICS reversed 
Rbm splitting but did not have any effect on vessel remodelling and angiogenic 
activities.  
 
Discussion: My studies revealed novel aspects of Rbm and vascular remodelling in BB 
from COPD subjects and S-N and for the first time showed that ICS are effective on 
Rbm changes in COPD. Rbm fragmentation, we think, is probably a consequence of the 
effects of proteolytic enzymes on the Rbm due to activation of epithelial-mesenchymal 
transition (EMT) by smoking. This is under more investigation in our group. My study 
could not explain the mechanisms to vessel changes in current smokers. Further studies 
to examine the role of other angiogenic/antiangiogenic factors are now needed. Absence 
of vascular changes in ES-COPD subjects may imply that vascular remodelling is 
reversible with smoking cessation, but to test this we need a longitudinal smoking 
cessation study.   
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Abbreviations and symbols 
Abbreviations 
AECOPD = Acute exacerbations of COPD 
AHR = Airway hyper-responsiveness, same as BHR 
AM = Alveolar macrophage 
ATS = American Thoracic Society 
BAL= Broncho-alveolar lavage 
BALF = Broncho-alveolar lavage fluid 
BB = Per-bronchoscopic bronchial biopsies 
BDR = Bronchodilator responsiveness 
BM = Basement membrane 
bFGF = Basic fibroblast growth factor 
BHR = Bronchial hyper-responsiveness 
CD (#) (like CD31 etc.) = Are surface antigens that are detectable by using different 
antibodies and are used to address different kinds of cells in the hematopoietic and tissue 
mononuclear-macrophage cellular system. 
Cm = centimeter 
CoR = Coefficient of repeatability 
CT-scan = Computerized tomography scan 
Dmin = The dose of methacholine that provokes 20% decrease in FEV1. It shows the 
presence and the severity of BHR. 
ECM = Extracellular matrix 
ELISA = Enzyme linked immunosorbent assay 
EMT = Epithelial-mesenchymal transition 
ERS = European Respiratory Society 
ES-COPD = Exsmoker COPD 
FEV1 = Forced expiratory volume in first second 
FER = Forced expiratory ratio = FEV1/FVC ratio x 100 
FOB = Fiberoptic bronchoscope 
FP = Fluticasone propionate 
FVC = Forced vital capacity 
DNA = deoxy ribonucleic acid 
GOLD = Global Initiative for Chronic Obstructive Lung Disease 
GR = Glucocorticoid receptor 
GM-CSF = Granulocyte-macrophage colony stimulating factor 
H-N = Healthy and nonsmoker 
HRCT = High resolution computerized scan 
Hyper- = A prefix that means increase of, e.g. hypervascularity means increased vessels 
Hypo- = A prefix that means decrease of, e.g. hypovascularity means decreased vessels 
IC = Inspiratory capacity 
ICS = Inhaled corticosteroid/inhaled corticosteroids 
I-кB = Inhibitor of кB   
IL = Interleukin 
LABA = Long-acting beta-adrenergic agonist 
LoA = Limits of agreement 
LP = lamina propria 
MAPK = Mitogen-activated protein kinase  
mg = milligram 
mm = millimeter 
MMP = Matrix metalloproteinase 
mRNA = Messenger ribonucleic acid 
NF-кB = Nuclear factory-kappa B 
NO = Nitric oxide 
PCR = Polymerase chain reaction 
PEF =  peak expiratory flow  
Percent vascularity = Area of vessels/area of the lamina propria examined 
Pi = Protease inhibitor = Alpha1-antitrypsine 
PI3K = Phosphoinositide 3 kinases 
PMN = Polymorphonuclear leukocyte 
Rbm = Reticular basement membrane 
RNA = Ribonucleic acid 
ROS = Reactive oxygen species 
S-COPD = Current smoker COPD 
SD = Standard deviation 
SE = Standard Error 
SFC = Salmeterol + fluticasone propionate 
SGRQ = St George’s Respiratory Questionnaire  
S-N = Smokers with normal lung function 
SNP = Single nucleotide polymorphism 
TGF-ß = Transforming growth factor-beta 
TIMP = Tissue inhibitor of metalloproteinases 
Vascular density = Number of vessels/ area of the lamina propria examined 
%vascular area = Percent vascular area 
VEGF = Vascular endothelial growth factor 
VEGFR = Vascular endothelial growth factor receptor 
VEGFR-1 = Flt-1, fms-like tyrosine kinase 
VEGFR-2 = KDR/FLK-1, Kinase-insert domain receptor/fetal liver kinase 
VEGFR-3 = Ftl4, fms-like tyrosine kinase 4 
Symbols: 
α = Alpha 
β = Beta 
γ = Gamma 
µ = Micro 
µm = Micrometer 
ν = Nu 
к = Kappa 
I = one 
II = Two 
III = Three 
IV = Four 
V = Five 
VIII = Eight 
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